✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Non-Sterile Compounding Pharmacy Market Research Report Information By-Product (Oral Medication, Topical Medication, Otologic/Nasal Medication), Application (Pain Medication, Hormone Replacement Therapy), End User (Compounding Pharmacy) - U.S. and Europe Forecast till 2032


ID: MRFR/Pharma/3248-CR | 101 Pages | Author: Rahul Gotadki| October 2017
Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 Report Prologue

2 Market Introduction

2.1 Definition 15

2.2 Scope of the Study 15

2.2.1 Research Objective 15

2.2.2 Assumptions 15

2.2.3 Limitations 15

3 Research Methodology

3.1 Introduction 17

3.2 Primary Research 18

3.3 Secondary research 18

3.4 Market Size Estimation 19

4 Market Dynamics

4.1 Introduction 21

4.2 Drivers 22

4.2.1 Increasing prevalence of chronic diseases (Impact weightage-35%) 23

4.2.2 Increasing need for customized medicine (Impact weightage-25%) 24

4.2.3 No availability of the alternative methods (Impact weightage-20%) 25

4.2.4 Increasing Geriatric Population (Impact weightage-20%) 26

4.3 Restrains 27

4.3.1 Poor reimbursement policies (Impact weightage-60%) 28

4.3.2 Strict Regulatory Rules (Impact weightage-40%) 29

4.4 Mega Trends 30

4.5 Opportunity 31

4.6 Macroeconomic indicators 31

5 Market Factor Analysis

5.1 Supply/Value Chain 32

5.1.1 Research & Development 32

5.1.2 Formulation 32

5.1.3 Marketing & Sales 32

5.1.4 Finish Products 33

5.2 Porters Five forces Model 33

5.2.1 Bargaining Power Of Suppliers 34

5.2.2 Bargaining Power Of Buyers 34

5.2.3 Threat Of New Entrants 34

5.2.4 Threat Of Substitutes 34

5.2.5 Intensity Of Rivalry 34

5.3 Investment Opportunity Analysis 35

5.4 Demand & Supply: Gap Analysis 35

5.5 Pricing Analysis 36

6 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

6.1 Introduction 37

6.2 Oral Medication 39

6.3 Topical Medications 42

6.4 Otologic/Nasal Medication 43

7 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

7.1 Introduction 44

7.2 Pain management 44

7.3 Hormone Replacement Therapy 45

8 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

8.1 Introduction 47

8.2 Hospital 48

8.3 Compounding Pharmacy 48

9 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Region

9.1 Introduction 49

9.2 U.S. 50

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.2.1 U.S. 51

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3 Europe 56

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.1 Western Europe 62

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.2 Germany 65

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.3 France 68

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.4 U.K. 71

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.5 Italy 74

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.6 Spain 77

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.7 The Netherlands 80

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.8 Rest of Western Europe 83

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.9 Eastern Europe 86

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

10 Company Landscape

10.1 Introduction: Key Players 90

10.2 Key Developments and Strategies 91

11 Company Profiles

11.1 Fagron 92

11.1.1 Company Overview 92

11.1.2 Financials 92

11.1.3 Products 92

11.1.4 Strategy 92

11.1.5 Key Developments 92

11.2 B.Braun Melsungen AG 93

11.2.1 Company Overview 93

11.2.2 Financials 93

11.2.3 Products 93

11.2.4 Strategy 93

11.2.5 Key Developments 93

11.3 Fresenius Kabi AG 94

11.3.1 Company Overview 94

11.3.2 Financials 94

11.3.3 Products 94

11.3.4 Strategy 94

11.3.5 Key Developments 94

11.4 True Nature Holding, Inc 95

11.4.1 Company Overview 95

11.4.2 Financials 95

11.4.3 Products 95

11.4.4 Strategy 95

11.4.5 Key Developments 95

11.5 Dougherty's Pharmacy, Inc. 96

11.5.1 Company Overview 96

11.5.2 Financials 96

11.5.3 Products 96

11.5.4 Strategy 96

11.5.5 Key Developments 96

11.6 Pharmedium 97

11.6.1 Company Overview 97

11.6.2 Financials 97

11.6.3 Products 97

11.6.4 Strategy 97

11.6.5 Key Developments 97

12 MRFR Conclusion

12.1 Key Findings 98

12.1.1 From CEO’s View Point 98

12.1.2 Unmet Needs 98

12.2 Key companies to watch 98

13 Appendix

13.1 Discussion Blue Print 99

14 List of Tables

TABLE 1 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2022- 2030 (USD Billion) 39

TABLE 2 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR ORAL MEDICATIONS,

BY REGION, 2022-2030 (USD Billion) 41

TABLE 3 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR TOPICAL MEDICATIONS,

BY REGION, 2022-2030 (USD Billion) 42

TABLE 4 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR OTOLOGIC/

NASAL MEDICATION, BY REGION, 2022-2030 (USD Billion) 43

TABLE 5 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 45

TABLE 6 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2022-2030 (USD Billion) 48

TABLE 7 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION,

2022-2030 (USD Billion) 49

TABLE 8 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2022-2030 (USD Billion) 51

TABLE 9 U.S. LIQUID PREPARATION MARKET, BY VOLUME, 2022-2030 (UNITS) 51

TABLE 10 U.S. SYRUPS MARKET, BY VOLUME, 2022-2030 (UNITS) 51

TABLE 11 U.S. SOLUTION MARKET, BY VOLUME, 2022-2030 (UNITS) 51

TABLE 12 U.S. SUSPENSION MARKET, BY VOLUME, 2022-2030 (UNITS) 52

TABLE 13 U.S. LIQUID PREPARATION MARKET, BY COMPANY WISE VOLUME 52

TABLE 14 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT , 2022-2030 (USD Billion) 52

TABLE 15 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 53

TABLE 16 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 53

TABLE 17 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 54

TABLE 18 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2022-2030 (USD Billion) 54

TABLE 19 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 55

TABLE 20 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2022-2030 (USD Billion) 57

TABLE 21 EUROPE LIQUID PREPARATION MARKET, BY VOLUME, 2022-2030 (UNITS) 57

TABLE 22 EUROPE SYRUPS MARKET, BY VOLUME, 2022-2030 (UNITS) 57

TABLE 23 EUROPE SOLUTION MARKET, BY VOLUME, 2022-2030 (UNITS) 58

TABLE 24 EUROPE SUSPENSION MARKET, BY VOLUME, 2022-2030 (UNITS) 58

TABLE 25 EUROPE LIQUID PREPARATION MARKET, COMPANY WISE VOLUME 58

TABLE 26 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 59

TABLE 27 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 59

TABLE 28 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 60

TABLE 29 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 60

TABLE 30 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 61

TABLE 31 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 61

TABLE 32 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2022-2030 (USD Billion) 62

TABLE 33 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 62

TABLE 34 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 63

TABLE 35 WESTERN EUROPE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 63

TABLE 36 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 64

TABLE 37 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2022-2030 (USD Billion) 64

TABLE 38 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 65

TABLE 39 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 65

TABLE 40 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 66

TABLE 41 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 66

TABLE 42 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 67

TABLE 43 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 67

TABLE 44 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 68

TABLE 45 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 68

TABLE 46 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 68

TABLE 47 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 69

TABLE 48 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 69

TABLE 49 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 70

TABLE 50 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2022-2030 (USD Billion) 70

TABLE 51 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 71

TABLE 52 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 71

TABLE 53 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 71

TABLE 54 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 72

TABLE 55 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 72

TABLE 56 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 73

TABLE 57 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2022-2030 (USD Billion) 73

TABLE 58 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 74

TABLE 59 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 74

TABLE 60 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 74

TABLE 61 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 75

TABLE 62 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 75

TABLE 63 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 76

TABLE 64 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2022-2030 (USD Billion) 76

TABLE 65 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 77

TABLE 66 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 77

TABLE 67 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2022-2030 (USD Billion) 77

TABLE 68 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 78

TABLE 69 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 78

TABLE 70 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2022-2030 (USD Billion) 79

TABLE 71 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2022-2030 (USD Billion) 79

TABLE 72 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2022-2030 (USD Billion) 80

TABLE 73 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2022-2030 (UNITS) 80

TABLE 74 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2022-2030 (USD Billion) 80

TABLE 75 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 81

TABLE 76 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 81

TABLE 77 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/

NASAL MEDICATIONS, 2022-2030 (USD Billion) 82

TABLE 78 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 82

TABLE 79 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2022-2030 (USD Billion) 83

TABLE 80 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCTS,

2022-2030 (USD Billion) 83

TABLE 81 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR

TOPICAL MEDICATIONS, 2022-2030 (USD Billion) 84

TABLE 82 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET,

FOR ORAL MEDICATIONS, 2022-2030 (USD Billion) 84

TABLE 83 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET,

FOR OTOLOGIC/NASAL MEDICATIONS, 2022-2030 (USD Billion) 85

TABLE 84 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 85

TABLE 85 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2022-2030 (USD Billion) 86

TABLE 86 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2022-2030 (USD Billion) 86

TABLE 87 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2022-2030 (USD Billion) 87

TABLE 88 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2022-2030 (USD Billion) 87

TABLE 89 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/

NASAL MEDICATIONS, 2022-2030 (USD Billion) 88

TABLE 90 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022-2030 (USD Billion) 88

TABLE 91 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2022-2030 (USD Billion) 89

TABLE 92 KEY DEVELOPMENTS AND STRATEGIES 91

15 List of Figures

FIGURE 1 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT MARKET SHARE,

2022 (%) 13

FIGURE 2 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, MARKET SHARE

2022 (%) 13

FIGURE 3 U.S. AND EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET BY END USER, MARKET SHARE

2022 (%) 14

FIGURE 4 MARKET STRUCTURE 16

FIGURE 5 RESEARCH PROCESS 17

FIGURE 6 FORECAST MODEL 20

FIGURE 7 VALUE CHAIN:NON-STERILE COMPOUNDING PHARMACY MARKET 32

FIGURE 8 PORTERS FIVE FORCES MODEL 33

FIGURE 9 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2022 & 2030 (USD Billion) 38

FIGURE 10 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2022- 2030 (USD Billion) 46

FIGURE 11 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET: COMPANY SHARE ANALYSIS

FOR THE KEY PLAYERS, 2022 (%) 90

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
pr-img
U.S. & Europe Non-Sterile Compounding Pharmacy Market is Expected to Grow at a CAGR over 5.7%...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)